These studies suggest that TRPV2 could be used as a prognostic marker for NSCLC patients in response to treatment, with CBD as a novel therapeutic agent in the context of cisplatin NSCLC. This evidence concerns the gene TRPV2 and non-small cell lung carcinoma.